Recombinant Mouse ARHGEF17 Protein Pre-coupled Magnetic Beads

• Cat.No.: ARHGEF17-693M-B
• Product Overview: The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations.

Specification

• Source: HEK293
• Species: Mouse
• Form: Solution
• Particle size: ~2 μm
• Beads Surface: Hydrophilic
• Capacity: > 200 pmol rabbit IgG/ mg beads
• Applications: Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification.
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions.
• Storage: 2-8℃. Do not to freeze thaw the Beads
• Concentration: 10mg beads/mL
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Arhgef17 Rho guanine nucleotide exchange factor (GEF) 17 [ Mus musculus ]
• Official Symbol: ARHGEF17
• Gene ID: 207212
• mRNA Refseq: NM_001081116.1
• Protein Refseq: NP_001074585.1
• UniProt ID: Q80U35

Reviews

03/05/2023

One of the key advantages of using ARHGEF17 protein in trials is its high quality.

12/19/2022

One of the standout factors that distinguishes the ARHGEF17 protein is the manufacturer's unwavering commitment to exceptional technical support.

02/10/2022

The ARHGEF17 protein offers exceptional quality that meets the rigorous demands of experimental research.

02/11/2019

This collaborative approach empowers me to integrate cutting-edge knowledge, explore innovative techniques, and expand the impact of my research.

08/30/2018

They ensure a consistent and reliable supply of ARHGEF17 protein, minimizing any potential disruptions in my experimental workflow.

12/11/2017

Whether investigating the role of ARHGEF17 in angiogenesis, vascular development, or disease pathways, this protein surpasses expectations and guarantees reliable results.

11/05/2017

Their excellent technical support, commitment to scientific collaboration, and efficient supply chain management greatly contribute to the success and productivity of my research.

08/07/2016

Its exceptional purity, consistency, and reliability make it an ideal choice for a wide range of research applications.

Q&As

Are there any known regulatory mechanisms that control ARHGEF17 expression or activity?

Yes, ARHGEF17 is subject to various regulatory mechanisms. Its expression can be regulated at the transcriptional level by certain signaling pathways or transcription factors. Additionally, post-translational modifications such as phosphorylation, acetylation, and ubiquitination can modulate ARHGEF17 activity and stability.

Can ARHGEF17 be used as a diagnostic or prognostic biomarker?

While ARHGEF17 has been implicated in various diseases, it is not currently used as a diagnostic or prognostic biomarker in clinical practice. However, ongoing research is exploring its potential as a biomarker, particularly in cancer, where altered ARHGEF17 expression or activity may be indicative of disease progression or response to therapy.

Are there any ongoing research studies or clinical trials related to ARHGEF17?

While there are no specific clinical trials or studies focused solely on ARHGEF17 currently registered, several ongoing research projects investigate its role in cancer, neurodegenerative diseases, and cardiovascular disorders. These studies aim to better understand the mechanisms of ARHGEF17 and explore its therapeutic potential.

Does ARHGEF17 have any interactions with other proteins?

Yes, ARHGEF17 interacts with several proteins to regulate its activity and function. It can interact with Rho GTPases, such as RhoA and Rac1, to facilitate their activation. Additionally, it can interact with other proteins involved in actin dynamics and cytoskeletal remodeling, such as myosin, microtubules, and actin-associated proteins.

Is ARHGEF17 involved in any signaling pathways?

ARHGEF17 is primarily involved in the regulation of Rho GTPase signaling pathways. It acts as a guanine nucleotide exchange factor (GEF) to activate RhoA and Rac1, triggering downstream signaling cascades involved in cytoskeletal changes, cell migration, and cytokinesis. Additionally, ARHGEF17 may be implicated in cross-talk with other signaling pathways, but further research is needed to fully elucidate its potential interactions.

Can ARHGEF17 be targeted by drugs or compounds?

Currently, there are no specific drugs or compounds designed to target ARHGEF17 directly. However, research efforts are focused on identifying small molecule inhibitors or modulators of the Rho GEF family that could indirectly impact ARHGEF17 activity and its associated signaling pathways.

What are the consequences of ARHGEF17 dysfunction or dysregulation?

Dysregulation of ARHGEF17 has been associated with several pathological conditions. Increased expression or activity of ARHGEF17 has been linked to cancer progression, metastasis, and invasion due to its role in promoting cell migration and cytoskeletal remodeling. Additionally, abnormal ARHGEF17 activity has been implicated in neurodegenerative diseases, cardiovascular disorders, and inflammatory processes.

What functions does ARHGEF17 have in cells?

ARHGEF17 is involved in various cellular processes including cell cycle regulation, cell migration, and cytokinesis. It helps regulate actin dynamics and cytoskeletal rearrangements, which are crucial for these cellular functions.

Are there any known genetic disorders or syndromes associated with mutations in ARHGEF17?

While ARHGEF17 mutations have not been directly linked to any specific genetic disorders or syndromes, dysregulation of its activity has been associated with various diseases. Altered expression or function of ARHGEF17 has been implicated in cancer progression, neurological disorders, and cardiovascular diseases.

What are the potential therapeutic implications of targeting ARHGEF17?

Targeting ARHGEF17 or its downstream signaling pathways holds therapeutic potential in various disease contexts. In cancer, inhibiting ARHGEF17 may impede tumor growth and metastasis by interfering with cell migration and invasion. Additionally, modulating ARHGEF17 activity could have implications in neurological disorders, cardiovascular diseases, and other conditions where Rho GTPase signaling is dysregulated.